Showing 321 - 340 results of 103,005 for search '(( 5 ((((teer decrease) OR (mean decrease))) OR (a decrease)) ) OR ( e point decrease ))', query time: 1.12s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324

    FABP5 overexpression decreases inflammation and increases innate immunity in primary NHBE cells. by Fabienne Gally (260470)

    Published 2013
    “…<p><b>A.</b> CS exposure decreases <i>P. aeruginosa</i> colony forming units (CFU) on primary NHBE cells overexpressing FABP5. …”
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331

    TRIM5 restriction of HIV-1 has decreased during evolution leading to humans. by Michael Emerman (12304)

    Published 2013
    “…<p>The shading of the rectangle represents the degree that TRIM5 will limit infection of HIV-1 (darker color means TRIM5 decreases HIV-1 infection more) and the X-axis indicates time in millions of years from the present. …”
  12. 332
  13. 333

    Tau phosphorylation is decreased in neurons treated with 20 mM KCl. by Nguyen-Vi Mohamed (323606)

    Published 2017
    “…The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. The signal of the phospho-antibodies was normalized to that of total Tau (n = 5, mean ± SEM, unpaired t-test two-tailed, *<i>P</i> < 0.05, ***<i>P</i> < 0.001). …”
  14. 334
  15. 335
  16. 336
  17. 337

    Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

    Published 2024
    “…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”
  18. 338
  19. 339
  20. 340

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”